Development  of  ciprofloxacin  radiopharmaceutical  formulation in single vial

Nurlaila Z; Maula Eka S; Eva Maria W

doi:10.14499/indonesianjpharm0iss0pp139-149

Development of ciprofloxacin radiopharmaceutical formulation in single vial

Nurlaila Z, Maula Eka S, Eva Maria W

Abstract

Bacterial infection diseases is the greatest death causes in Indonesia. Detection of the deep-seated infection location caused by the gram positive and gram negative bacteries could be done with nuclear technique using 99mTc-ciprofloxacin radiopharmaceutical. In order to fulfill the necessity of this radiopharmaceutical, the development of formulation in single vial based on Sn(II) chloride and tartaric acid instead of Sn(II) tartrat has been carried out. The aim of this investigation is to obtained the optimum condition of 99mTc-ciprofloxacin preparation with maximum labelling efficiency. Several parameters influencing the labelling process of 99mTc-ciprofloxacin such as the amount of tartaric acid, pH of the reaction, the amount of Sn(II) ion as a reducing agent and the incubation time has been studied. The labelling efficiency and the radiochemical purity of 99mTc-ciprofloxacin were determined by double chromatography system using Whatman I/methyl ethyl keton to determine the free 99mTc-pertechnetate and ITLCSG/(ethanol:water:ammonia = 2:5:1) to separate the free 99mTc-reduced. The optimum preparation condition was obtained at pH = 2.95-3.20, 2 mg of ciprofloxacin, 0.06 µg of tartaric acid, 50 µg of SnCl22H2O and 15 minutes incubation time at room temperature, gave 90-93 % of labelling efficiency, in wchich was stable for 20 minutes at room temperature. Beside that, studies on the effect of Na99mTcO4 solution volume to the 99mTc-ciprofloxacin labelling efficiency was carried out. Labelling with up to 0.3 mL of Na99mTcO4 solution volume gave less than 90 % labelling efficiency.

Key words: radiopharmaceutical, ciprofloxacin, 99mTc, single vial

Full Text:

PDF 139-149

References

Bhardwaj N., Bhatnagar A., and Singh A. K., 2005, Development and evaluation of a single vial cold kit for infection imaging:Tc-99m ciprofloxacin, World J. Nucl. Med., 4, 244-251.

Britton K. E., Vinjamuri S., Hall A. V., Solanki K., Siraj Q. H., Bomanji J., and Das S., 1997, Clinical evaluation of technetium-99m Infecton for the localisation of bacterial infection. Eur. J. Nucl. Med., 24, 553-556.

Britton K. E., Wareham D. W., Das S., Solanki K. K., Amarat H., Bhatnagar A., Katamihardja A. H. S., Malamitsi J., Moustafa H. M., Soroa V. E., Sundram F. X., and Padhy A. K., 2002, Imaging bacterial infection with 99mTc-ciprofloxacin (Infecton). J. Clin. Pathol., 55, 817-823.

Dumarey N., Blocklet D., Appelboom T., Tant L., andSchoutens A., 2002, Infecton is not specific for bacterial osteo-articular infective patology, Eur. J. Nucl. Med., Mol. Imaging, 29, 530-535.

Gano L., Patricio L., Cantiho G., Pena H., Martins T., and Marques E., 1998, Ciprofloxacin in imaging of infective versus sterile inflamation, IAEA-TecDoc1029, Vienna, 213-220.

Hasan Basry T., Nurlaila Z., and Rukmini I., 2005, Formulasi radiofarmaka 99mTc-siprofloksasin untuk diagnosis infeksi, Prosiding Seminar Nasional Sains dan Teknik Nuklir, Bandung, Puslitbang Teknik Nuklir-BATAN, 38-45.

Kleisner I., Komarek P., Komarkova I., and Konopkova M., 2002, A new technique of 99mTcciprofloxacin kit preparation, Nuklearmedizin, 41, 224-229.

Larikka M. J., Ahonen A. K., Niemela O., Puronto O., Junila J. A., Hamalainen M. M., Britton K., and Syrjala H. P., 2002, 99mTc-ciprofloxacin (Infecton) imaging in the diagnosis of knee prosthesis infection, Nucl. Med. Commun., 23, 167-170.

Martins P. A., Faintuch B. L., and Pereira N. P. S., 2001, Optimization of labeling ciprofloxacin with 99mTc and biodistribution in normal and injected rats, J. Nucl. Med., 42, 264P.

Nurlaila Z., Basuki H., and Rukmini I., 2009, Pengembangan dan aplikasi klinis kit-kering radiofarmaka siprofloksasin, Jurnal Sains dan Teknologi Nuklir, X(1), 11-23.

Owunwanne A., Patel M., and Sadek S., 1995, The Handbook of Radiopharmaceuticals, 1st ed.,

London:Chapman & Hall Medical, pp.18–22.

Rukmini I., 2005, Desain kit kering radiofarmaka siprofloksasin, P3TkN/Lap301008/ NP/2005.

Saha G. B., 2004, Fundamentals of Nuclear Pharmacy, 5th ed., New York: Springer,.101.

Siaens R. H., Rennen H. J., Boerman O.C., Dierckx R., Slegers G., 2004, Synthesis and comparison of 99mTc-enfrofloxacin and 99mTc-ciprofloxacin, J. Nucl.Med.,45(12), 2088-2094.

Sonmezoglu K., Sonmezoglu M., Halac M., Akgun I., Turkmen C., Onsel C., Kanmaz B., Solanki K., Britton K.E., and Uslu I., 2001, Usefulness of 99mTc-ciprofloxacin (Infecton) scan in diagnosis of chronic orthopedic infections: comparative study with 99mTc-HMPAO leukocyte scintigraphy, J. Nucl. Med., 42, 567-574.

Yana S., Rizky J. S., and Nurlaila Z., 2007, Biodistribusi dan uji clearance 99mTc-siprofloksasin pada mencit (Mus musculus) yang terinfeksi bakteri Escherichia coli, Prosiding Seminar Nasional Sains dan Teknik Nuklir, Bandung, PTNBR-BATAN, 393-397.

DOI: http://dx.doi.org/10.14499/indonesianjpharm0iss0pp139-149